Abstract
Clozapine's use in the management of patients with treatment‐resistant schizophrenia has been limited by the occurrence of significant side effects. Also, because its elimination is primarily mediated by multiple drug‐metabolizing enzymes, the potential for drug–drug interaction is high. The following case described an elderly patient who developed dystonic reactions with concurrent administration of clozapine and cinacalcet, a calcimimetic used to treat patients with tertiary hyperparathyroidism, parathyroid carcinoma, and primary hyperparathyroidism.1
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
